BR112012010635A2 - hidratos cristalinos, composições farmaceuticas e seus métodos de preparação e métodos para uso dos mesmos - Google Patents

hidratos cristalinos, composições farmaceuticas e seus métodos de preparação e métodos para uso dos mesmos

Info

Publication number
BR112012010635A2
BR112012010635A2 BR112012010635A BR112012010635A BR112012010635A2 BR 112012010635 A2 BR112012010635 A2 BR 112012010635A2 BR 112012010635 A BR112012010635 A BR 112012010635A BR 112012010635 A BR112012010635 A BR 112012010635A BR 112012010635 A2 BR112012010635 A2 BR 112012010635A2
Authority
BR
Brazil
Prior art keywords
methods
preparation
pharmaceutical compositions
crystalline hydrates
hydrates
Prior art date
Application number
BR112012010635A
Other languages
English (en)
Inventor
Que Feng
Wang Ying
Original Assignee
Sichuan Beilike Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Beilike Biotechnology Llc filed Critical Sichuan Beilike Biotechnology Llc
Publication of BR112012010635A2 publication Critical patent/BR112012010635A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012010635A 2009-11-04 2010-11-03 hidratos cristalinos, composições farmaceuticas e seus métodos de preparação e métodos para uso dos mesmos BR112012010635A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25792409P 2009-11-04 2009-11-04
PCT/CN2010/078377 WO2011054292A1 (en) 2009-11-04 2010-11-03 Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof

Publications (1)

Publication Number Publication Date
BR112012010635A2 true BR112012010635A2 (pt) 2018-03-20

Family

ID=43969571

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010635A BR112012010635A2 (pt) 2009-11-04 2010-11-03 hidratos cristalinos, composições farmaceuticas e seus métodos de preparação e métodos para uso dos mesmos

Country Status (11)

Country Link
US (1) US8916567B2 (pt)
EP (1) EP2496563A4 (pt)
JP (1) JP2013510098A (pt)
KR (1) KR20130028703A (pt)
CN (1) CN102256951B (pt)
AU (1) AU2010314593B2 (pt)
BR (1) BR112012010635A2 (pt)
HK (1) HK1164311A1 (pt)
RU (1) RU2012122767A (pt)
WO (1) WO2011054292A1 (pt)
ZA (1) ZA201203531B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013182070A1 (zh) * 2012-06-08 2013-12-12 四川贝力克生物技术有限责任公司 一种用于预防或治疗分支杆菌疾病的药物
CN107456442A (zh) * 2016-06-03 2017-12-12 四川赛卓药业股份有限公司 一种噁唑烷酮化合物的亚微乳注射剂及其制备方法和用途
CN107648181B (zh) * 2016-07-25 2021-05-04 广东赛法洛药业有限公司 一种利他唑酮磷脂复合物及其制备方法和应用
CN112409285A (zh) * 2020-11-30 2021-02-26 山东金城昆仑药业有限公司 噁唑烷酮类化合物的晶型及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
ATE372966T1 (de) * 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AU729745B2 (en) * 1997-07-11 2001-02-08 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
GB9821938D0 (en) * 1998-10-09 1998-12-02 Zeneca Ltd Chemical compounds
CN1155585C (zh) * 2001-12-19 2004-06-30 中国医学科学院医药生物技术研究所 3,5－取代噁唑烷酮衍生物及其制备方法和应用
US20070185132A1 (en) * 2003-07-02 2007-08-09 Yasumichi Fukuda Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo
CA2572207A1 (en) * 2004-06-29 2006-10-19 Teva Pharmaceutical Industries Ltd. Solid forms of linezolid and processes for preparation thereof
CN100538355C (zh) * 2007-03-19 2009-09-09 四川贝力克生物技术有限责任公司 3,5-取代噁唑烷酮类化合物的纯度的检测方法
CN100473385C (zh) * 2007-03-19 2009-04-01 四川贝力克生物技术有限责任公司 3,5-取代噁唑烷酮类化合物的溶解方法
CN100582749C (zh) * 2007-03-19 2010-01-20 四川贝力克生物技术有限责任公司 3,5-取代噁唑烷酮类化合物的含量测定方法

Also Published As

Publication number Publication date
HK1164311A1 (en) 2012-09-21
US20110136822A1 (en) 2011-06-09
EP2496563A1 (en) 2012-09-12
US8916567B2 (en) 2014-12-23
AU2010314593A1 (en) 2012-06-14
EP2496563A4 (en) 2013-04-03
AU2010314593B2 (en) 2015-05-21
CN102256951A (zh) 2011-11-23
ZA201203531B (en) 2013-07-31
CN102256951B (zh) 2013-07-17
RU2012122767A (ru) 2013-12-10
WO2011054292A1 (en) 2011-05-12
KR20130028703A (ko) 2013-03-19
JP2013510098A (ja) 2013-03-21

Similar Documents

Publication Publication Date Title
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
HK1164050A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BR112014001991A2 (pt) certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112013011949A2 (pt) "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis"
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BR112013026410A2 (pt) compostos antimicrobianos e métodos de preparação e uso dos mesmos
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BRPI0922174A2 (pt) preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0908175A2 (pt) derivados de polimixina e composição farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.